The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing
Abstract
Adoptive T cell immunotherapy is a promising treatment strategy for epithelial ovarian cancer (EOC). However, programmed death ligand‐1 (PD‐L1), highly expressed on EOC cells, interacts with programmed death‐1 (PD‐1), expressed on T cells, causing immunosuppression. This study aims to block PD‐1/PD‐L1 interactions by delivering PD‐L1 siRNA, using various folic acid (FA)–functionalized polyethylenimine (PEI) polymers, to SKOV‐3‐Luc EOC cells, and investigate the sensitization of the EOC cells to T cell killing. To enhance siRNA uptake into EOC cells, which over express folate receptors, PEI is modified with FA or PEG–FA so that siRNA is complexed into nanoparticles with folate molecules on the surface. PEI modification with a single functional group lowers the polymer cytotoxicity compared to unmodified PEI. FA‐conjugated polymers increase siRNA uptake into SKOV‐3‐luc cells and decrease unspecific uptake into monocytes. All polymers result in 40% to 50% PD‐L1 protein knockdown. Importantly, SKOV‐3‐Luc cells treated with either PEI–FA or PEI– polyethylene glycol (PEG)–FA/PD‐L1 siRNA complexes are up to twofold more sensitive to T cell killing compared to scrambled siRNA treated controls. These findings are the first to demonstrate that PD‐L1 knockdown in EOC cells, via siRNA/FA‐targeted delivery, are able to sensitize cancer cells to T cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Folate-decorated nanogels for targeted therapy of ovarian cancer
Nukolova, N. V., Oberoi, H. S., Cohen, S. M., Kabanov, A. V., & Bronich, T. K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.006 · Cited by 223
Cited by
Cancer nanomedicine for combination cancer immunotherapy
Nam, J., Son, S., Park, K. S., Zou, W., Shea, L. D., & Moon, J. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0108-1 · Cited by 940
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Wu, Y., Chen, W., Xu, Z. P., & Gu, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02022 · Cited by 419
Feng, X., Xu, W., Li, Z., Song, W., Ding, J., & Chen, X. (2019) · Advanced Science · doi:10.1002/advs.201900101 · Cited by 363
Current understanding of interactions between nanoparticles and the immune system
Dobrovolskaia, M. A., Shurin, M., & Shvedova, A. A. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.022 · Cited by 309
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
Metadata
- Authors
- Teo, P. Y., Yang, C., Whilding, L. M., Parente‐Pereira, A. C., Maher, J., George, A. J. T., Hedrick, J. L., Yang, Y. Y., & Ghaem‐Maghami, S.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2015-04-11
- Volume
- 4
- Issue
- 8
- Pages
- 1180-1189
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2033867600
- Cited by
- 172
- References
- 8
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing. https://app.cochat.ai/papers/10.1002/adhm.201500089
- The paper
- Teo, P. Y., Yang, C., Whilding, L. M., Parente‐Pereira, A. C., Maher, J., George, A. J. T., Hedrick, J. L., Yang, Y. Y., & Ghaem‐Maghami, S. (2015). Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.201500089
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.